Indivior PLC
LSE:INDV
Intrinsic Value
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. [ Read More ]
The intrinsic value of one INDV stock under the Base Case scenario is 2 661.78 GBX. Compared to the current market price of 1 408 GBX, Indivior PLC is Undervalued by 47%.
Valuation Backtest
Indivior PLC
Run backtest to discover the historical profit from buying and selling INDV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Indivior PLC
Current Assets | 1.3B |
Cash & Short-Term Investments | 410m |
Receivables | 254m |
Other Current Assets | 599m |
Non-Current Assets | 691m |
Long-Term Investments | 41m |
PP&E | 117m |
Intangibles | 237m |
Other Non-Current Assets | 296m |
Current Liabilities | 1.3B |
Accounts Payable | 67m |
Accrued Liabilities | 676m |
Other Current Liabilities | 562m |
Non-Current Liabilities | 649m |
Long-Term Debt | 270m |
Other Non-Current Liabilities | 379m |
Earnings Waterfall
Indivior PLC
Revenue
|
1.1B
USD
|
Cost of Revenue
|
-177m
USD
|
Gross Profit
|
916m
USD
|
Operating Expenses
|
-646m
USD
|
Operating Income
|
270m
USD
|
Other Expenses
|
-268m
USD
|
Net Income
|
2m
USD
|
Free Cash Flow Analysis
Indivior PLC
INDV Profitability Score
Profitability Due Diligence
Indivior PLC's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Indivior PLC's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
INDV Solvency Score
Solvency Due Diligence
Indivior PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Indivior PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INDV Price Targets Summary
Indivior PLC
According to Wall Street analysts, the average 1-year price target for INDV is 2 512.6 GBX with a low forecast of 2 413.9 GBX and a high forecast of 2 625 GBX.
Shareholder Return
INDV Price
Indivior PLC
Average Annual Return | 87.5% |
Standard Deviation of Annual Returns | 74.43% |
Max Drawdown | -48% |
Market Capitalization | 1.9B GBX |
Shares Outstanding | 136 526 400 |
Percentage of Shares Shorted | 53% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. The company is headquartered in Slough, Berkshire and currently employs 802 full-time employees. The company went IPO on 2014-12-23. The firm is engaged in developing medicines to treat addiction and serious mental illnesses. The company focuses to build a portfolio of opioid dependence treatments. The company has a pipeline of product candidates designed to address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as new therapies to address the needs of people suffering from alcohol, stimulant and cannabis use disorders. Its pipeline products include INDV-3000 - Selective Dopamine D3-receptor Antagonist, RBP-6000 - Buprenorphine XR injection, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet and Buprenorphine Sublingual Tablet, among others. Its portfolio of products is available in more than 40 countries.
Officers
The intrinsic value of one INDV stock under the Base Case scenario is 2 661.78 GBX.
Compared to the current market price of 1 408 GBX, Indivior PLC is Undervalued by 47%.